{"id":"NCT01541735","sponsor":"Coordinación de Investigación en Salud, Mexico","briefTitle":"Pantoprazole on Insulin Secretion in Diabetes","officialTitle":"Effect of Pantoprazole on Insulin Secretion in Patients With Type 2 Diabetes","status":"COMPLETED","phase":"PHASE2","dates":{"start":"2012-01","primaryCompletion":"2013-03","completion":"2013-05","firstPosted":"2012-03-01","resultsPosted":"2014-02-21","lastUpdate":"2014-02-21"},"enrollment":14,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Type 2 Diabetes"],"interventions":[{"type":"DRUG","name":"Pantoprazole","otherNames":["Pantozol"]},{"type":"DRUG","name":"placebo","otherNames":[]}],"arms":[{"label":"Placebo","type":"PLACEBO_COMPARATOR"},{"label":"Pantoprazole","type":"EXPERIMENTAL"}],"summary":"The purpose of the study is to evaluate the effect of pantoprazole on insulin secretion in drug-naïve patients with type 2 diabetes.","primaryOutcome":{"measure":"First Phase of Insulin Secretion","timeFrame":"Change from Baseline at 45 days. (plus or minus 3 days)","effectByArm":[{"arm":"Pantoprazole","deltaMin":13.8,"sd":5.5},{"arm":"Placebo","deltaMin":15.9,"sd":9.3}],"pValues":[]},"eligibility":{"minAge":"30 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":8,"exclusionCount":6},"locations":{"siteCount":1,"countries":["Mexico"]},"refs":{"pmids":["25704601"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":7},"commonTop":[]}}